Over the past 10 years, teams of oncology disease specific experts, supported by biostatisticians and experts in genomics, helped COTA create a digital map of all of cancer, called COTA Nodal Addresses (CNA). CNAs are currently in use by payers, pharma/biotech and practicing oncologists. CNAs take into account all of the relevant diagnostic (staging, genomics, etc.) and prognostic information embodied by a cancer as well as the intent of therapy and progressionstatus.
Andrew L. Pecora M.D. FACP CPE, founder of COTA and architect of CNAs said, “Using COTA’s oncology expertise, the trillions of possible permutations have been reduced to a limited number, which then can be used to compare similar cancer types. Any differences in outcomes in a CNA grouping are likely to be more an effect of behavioral differences between providers and less an effect of biologic differences between patients.”
To help focus treatments and reduce skyrocketing costs that could result in rationed care, COTA is in the process of digitally mapping other medical conditions where costs and variances in care are high.
About COTA, Inc.
Developed by world-leading oncologists, COTA, Inc. has developed the unique CNA (COTA Nodal Address) System for precisely classifying cancer patients, and the systems and methodologies to enable doctors and health plans to improve patient care and move from fee-for-service to value-based reimbursement models. COTA offers providers, patients and payers with the actionable, real-time insights they need to improve clinical outcomes, while reducing the costs. Based in New York City, the Company’s mission is to enable optimal care for every cancer patient. To learn more about COTA, call (866) 648-3833 or visitwww.cotatrack.com.
Barbara Jacoby is an award winning blogger that has contributed her writings to multiple online publications that have touched readers worldwide.